BioNTech SE
BNTX
$86.34
-$1.55-1.76%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 1.59B | 974.46M | 182.54M | 1.37B | 4.37B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.59B | 974.46M | 182.54M | 1.37B | 4.37B |
| Cost of Revenue | 192.82M | 176.11M | 177.32M | 102.95M | 187.49M |
| Gross Profit | 1.40B | 798.36M | 5.22M | 1.27B | 4.18B |
| SG&A Expenses | 136.08M | 172.95M | 153.26M | 141.13M | 137.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 4.41M | -24.49M | -18.83M | -59.52M | -211.20M |
| Total Operating Expenses | 955.36M | 866.49M | 718.19M | 542.75M | 634.61M |
| Operating Income | 636.90M | 107.97M | -535.65M | 826.72M | 3.74B |
| Income Before Tax | 713.99M | 247.51M | -448.68M | 758.94M | 3.24B |
| Income Tax Expenses | 221.02M | 72.71M | -241.43M | 220.38M | 913.35M |
| Earnings from Continuing Operations | 492.97M | 174.80M | -207.25M | 538.56M | 2.33B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 492.97M | 174.80M | -207.25M | 538.56M | 2.33B |
| EBIT | 636.90M | 107.97M | -535.65M | 826.72M | 3.74B |
| EBITDA | 673.08M | 152.92M | -500.93M | 860.39M | 3.75B |
| EPS Basic | 2.06 | 0.73 | -0.86 | 2.22 | 9.58 |
| Normalized Basic EPS | 1.94 | 0.65 | -1.16 | 1.96 | 8.34 |
| EPS Diluted | 2.04 | 0.73 | -0.86 | 2.20 | 9.46 |
| Normalized Diluted EPS | 1.93 | 0.65 | -1.16 | 1.94 | 8.24 |
| Average Basic Shares Outstanding | 239.74M | 239.70M | 241.01M | 242.61M | 242.93M |
| Average Diluted Shares Outstanding | 241.00M | 239.70M | 241.01M | 244.98M | 246.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
